sofosbuvir-velpatasvir drug combination: Clinical Trials

19 completed, 1 active not recruiting, 1 recruiting. 21 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	21	Completed 19, Active not recruiting 1, Recruiting 1
Phase 3	2	Completed 2
Phase 1	1	Completed 1

Follow sofosbuvir-velpatasvir drug combination: new trials by email Literature Review of sofosbuvir-velpatasvir drug combination trials Research Report on sofosbuvir-velpatasvir drug combination

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients Epclusa - End Stage Renal Disease	Phase 2	Completed	University of Pennsylvania	201	2021-06-22	2026-03-12
The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients sofosbuvir/velpatasvir - Liver Transplant, Hepatitis C	Phase 2	Completed	Fernanda P Silveira, MD, MS	5	2019-08-15	2026-04-30
The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients sofosbuvir/velpatasvir - Kidney Transplantation, Hepatitis C	Phase 2	Active not recruiting	Amit D Tevar, MD	30	2019-05-29	2025-11-06
Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Sofosbuvir and Velpatasvir - Hepatitis C, Acute Hepatitis C	Phase 2	Completed	Hannover Medical School	20	2019-05-28	2021-07-06
Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C	Phase 2 / Phase 3	Completed	Ohio State University	54	2019-03-22	2023-09-13
Transplanting Hepatitis C Lungs Into Negative Lung Recipients Zepatier, Epclusa - Lung Diseases	Phase 1 / Phase 2	Completed	University of Pennsylvania	10	2018-12-12	2023-04-14
Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) CDI-31244, SOF/VEL - Chronic Hepatitis C	Phase 2	Completed	Cocrystal Pharma, Inc.	12	2018-06-26	2021-04-28
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients Epclusa - Heart Failure	Phase 2	Recruiting	Baylor Research Institute	15	2018-03-20	2026-01-22
Expanding the Pool in Orthotopic Heart Transplantation sofosbuvir/velpatasvir - Hepatitis C, Heart Transplant	Phase 2	Completed	Mary E. Keebler, MD	20	2017-08-01	2026-06-22
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease SOF/VEL - Chronic Hepatitis C	Phase 2	Completed	Gilead Sciences	59	2017-03-22	2020-03-06
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	216	2017-01-26	2020-10-08
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	32	2017-01-23	2020-03-02
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	204	2016-07-29	2018-11-27
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	79	2016-07-27	2018-11-14
Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	9	2016-06-12	2019-02-06
Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Ledipasvir+Sofosbuvir, Sofosbuvir+Velpatasvir - Indolent B-cell Lymphoma, Hepatitis C	Phase 2	Completed	Fondazione Italiana Linfomi - ETS	40	2016-03-01	2023-03-31
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia Harvoni, Epclusa - Hepatitis C, Cryoglobulinemia	Phase 2 / Phase 3	Completed	Icahn School of Medicine at Mount Sinai	10	2016-02-01	2020-12-17
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection VOX, SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	205	2015-02-17	2020-03-06
Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection VOX, SOF/VEL - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	128	2015-02-16	2020-03-03
Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study SOF/VEL, RBV - Hepatitis C Virus Infection	Phase 2	Completed	Gilead Sciences	69	2014-12-01	2018-11-16

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Hepatitis C (15)  ·  Hepatitis C, Chronic (3)  ·  Cryoglobulinemia (1)  ·  Heart Failure (1)  ·  Infections (1)  ·  Kidney Failure, Chronic (1)  ·  Lung Diseases (1)

Sponsors

Gilead Sciences (10)  ·  University of Pennsylvania (2)  ·  Amit D Tevar, MD (1)  ·  Baylor Research Institute (1)  ·  Cocrystal Pharma, Inc. (1)  ·  Fernanda P Silveira, MD, MS (1)  ·  Fondazione Italiana Linfomi - ETS (1)  ·  Hannover Medical School (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Mary E. Keebler, MD (1)  ·  Ohio State University (1)

Countries

United States (14)  ·  New Zealand (6)  ·  Puerto Rico (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Italy (2)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Switzerland (1)

Top investigators

Fernanda Silviera, MD (2)  ·  Amit Tevar, MD (1)  ·  Joel Chua, MD (1)  ·  Luca Arcaini (1)  ·  Markus Cornberg, Prof. Dr. (1)  ·  Naudia Jonassaint, MD (1)  ·  Peter Gorevic, MD (1)  ·  Peter Reese, MD, MSCE (1)  ·  Peter Reese, MD, PhD (1)  ·  Reem Daloul, MD (1)  ·  Shelley A Hall, MD, FACC, FHFSA (1)

Results publications

PMID 27240903, PMID 27486033, PMID 27486034, PMID 28137593, PMID 29958855, PMID 31195062, PMID 34596223, PMID 35714311, PMID 36852107, PMID 38644678

NIH funding

2016 (5), 2018 (1), U01DK126654 (1)